.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
Tyrosine Hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis, catalyzing the conversion of L-tyrosine to L-DOPA. This page provides comprehensive information about TH structure, function, and its critical role in dopaminergic neuron survival and neurodegenerative diseases.
Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in dopamine biosynthesis: the conversion of L-tyrosine to L-DOPA. This enzyme requires tetrahydrobiopterin (BH4) and iron as cofactors. TH is expressed primarily in catecholaminergic neurons of the substantia nigra, locus coeruleus, and other brain regions. TH activity is tightly regulated by phosphorylation at multiple sites in response to neuronal activity.
TH is a homotetramer of identical subunits. Each subunit has an N-terminal regulatory domain with phosphorylation sites, a catalytic domain, and a C-terminal domain. The enzyme is subject to complex regulation by phosphorylation, feedback inhibition by catecholamines, and protein-protein interactions.
TH (tyrosine hydroxylase) catalyzes the rate-limiting step in dopamine biosynthesis: the conversion of L-tyrosine to L-DOPA. This enzyme requires tetrahydrobiopterin (BH4) and iron as cofactors. TH activity is regulated by phosphorylation at multiple sites in response to neuronal activity.
TH mutations cause Segawa syndrome (dopa-responsive dystonia), a disorder characterized by childhood-onset dystonia and parkinsonism. TH deficiency leads to impaired dopamine synthesis. TH activity is reduced in PD substantia nigra, contributing to motor symptoms.
L-DOPA/carbidopa remains the primary treatment for TH-related disorders. Gene therapy to deliver TH is in clinical trials for PD. Small molecules that enhance TH activity or stability are being explored. BH4 supplementation may help in cofactor deficiency.
The study of Th Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.